Pfizer's (PFE) Talazoparib Emerges Superior In EMBRACA Study
Zacks Investment Research | Dec 10, 2017 10:36PM ET
Pfizer Inc. (NYSE:PFE) announced superiority of its breast cancer candidate – talazoparib – over chemotherapy in improving progression free survival (“PFS”) in a phase III study, EMBRACA.
Talazoparib is an investigation dual-mechanism poly ADP ribose polymerase (“PARP”) inhibitor. The company will present the data from the study at the 2017 San Antonio Breast Cancer Symposium.
Shares of Pfizer have gained 9.3% in the past six months, outperforming the industry ’s rise of 4.4% in that period.
The EMBRACA study evaluated talazoparib as a single agent in patients with germline BRCA-positive breast cancer who have received prior chemotherapy treatment. The candidate achieved a significant reduction of 46% in the risk of disease progression as the median PFS was 8.6 months in the talazoparib arm versus 5.6 month in the chemotherapy arm.
Moreover, 62.6% of patients in talazoparib arm achieved complete or partial response against 27.2% of patients receiving chemotherapy.
PARP inhibition is a new targeted therapy, which inhibits repair of the DNA of the cell, thus destroying the cell. The label expansion application of AstraZeneca’s (NYSE:AZN) PARP inhibitor, Lynparza, is under review in the United States. Meanwhile, Clovis Oncology, Inc. (NASDAQ:CLVS) has collaborated with Bristol-Myers Squibb Company (NYSE:BMY) to develop its PARP inhibitor in combination with the latter’s PD-1 immune checkpoint inhibitor, Opdivo, in breast cancer.
Apart from talazoparib, Pfizer is also developing its key drug, Ibrance for treating advanced or high-risk early breast cancer. Ibrance is currently approved for HER2-negative advanced or metastatic breast cancer.
Pfizer, Inc. Price
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.